Sanofi (EPA:SAN) has been assigned a €93.00 ($110.71) price target by research analysts at Deutsche Bank in a research report issued on Friday. The firm presently has a “buy” rating on the stock. Deutsche Bank’s price objective suggests a potential upside of 27.48% from the company’s current price.
Other analysts have also recently issued reports about the company. Morgan Stanley set a €92.00 ($109.52) price target on Sanofi and gave the stock a “buy” rating in a research report on Friday, October 6th. Jefferies Group set a €80.00 ($95.24) price target on Sanofi and gave the stock a “neutral” rating in a research report on Tuesday. S&P Global set a €83.00 ($98.81) price target on Sanofi and gave the stock a “neutral” rating in a research report on Friday, November 3rd. Goldman Sachs Group set a €82.00 ($97.62) price target on Sanofi and gave the stock a “neutral” rating in a research report on Friday, November 3rd. Finally, set a €78.00 ($92.86) price target on Sanofi and gave the stock a “neutral” rating in a research report on Friday, November 3rd. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and five have assigned a buy rating to the company’s stock. Sanofi currently has a consensus rating of “Hold” and an average target price of €86.88 ($103.42).
Shares of Sanofi (EPA SAN) traded up €0.58 ($0.69) on Friday, hitting €72.95 ($86.85). The stock had a trading volume of 2,260,000 shares, compared to its average volume of 2,240,000. Sanofi has a 12-month low of €71.06 ($84.60) and a 12-month high of €92.97 ($110.68). The company has a market cap of $92,150.00 and a PE ratio of 20.21.
ILLEGAL ACTIVITY WARNING: “Deutsche Bank Analysts Give Sanofi (SAN) a €93.00 Price Target” was published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/20/deutsche-bank-analysts-give-sanofi-san-a-93-00-price-target.html.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.